Cargando…
Shaofu Zhuyu decoction ameliorates obesity-mediated hepatic steatosis and systemic inflammation by regulating metabolic pathways
Shaofu Zhuyu decoction (SFZYD, also known as Sobokchugeo-tang), a classical prescription drug in traditional East Asian medicine, has been used to treat blood stasis syndrome (BSS). Hepatic steatosis is the result of excess caloric intake, and its pathogenesis involves internal retention of phlegm a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5453538/ https://www.ncbi.nlm.nih.gov/pubmed/28570676 http://dx.doi.org/10.1371/journal.pone.0178514 |
_version_ | 1783240680224587776 |
---|---|
author | Hong, Moonju Jung, Jeeyoun Park, Hee-Sook Lee, So Min Jeong, Nam-Joo Kim, Soon-Hee Lee, Kyoung-Won Lee, Ju-A Kim, Myung-Sunny |
author_facet | Hong, Moonju Jung, Jeeyoun Park, Hee-Sook Lee, So Min Jeong, Nam-Joo Kim, Soon-Hee Lee, Kyoung-Won Lee, Ju-A Kim, Myung-Sunny |
author_sort | Hong, Moonju |
collection | PubMed |
description | Shaofu Zhuyu decoction (SFZYD, also known as Sobokchugeo-tang), a classical prescription drug in traditional East Asian medicine, has been used to treat blood stasis syndrome (BSS). Hepatic steatosis is the result of excess caloric intake, and its pathogenesis involves internal retention of phlegm and dampness, blood stasis, and liver Qi stagnation. To evaluate the effects of treatment with SFZYD on obesity-induced inflammation and hepatic steatosis, we fed male C57BL/6N mice a high fat diet (HFD) for 8 weeks and then treated them with SFZYD by oral gavage for an additional 4 weeks. The results of histological and biochemical examinations indicated that SFZYD treatment ameliorates systemic inflammation and hepatic steatosis. A partial least squares-discriminant analysis (PLS-DA) scores plot of serum metabolites showed that HFD mice began to produce metabolites similar to those of normal chow (NC) mice after SFZYD administration. We noted significant alterations in the levels of twenty-seven metabolites, alterations indicating that SFZYD regulates the TCA cycle, the pentose phosphate pathway and aromatic amino acid metabolism. Increases in the levels of TCA cycle intermediate metabolites, such as 2-oxoglutaric acid, isocitric acid, and malic acid, in the serum of obese mice were significantly reversed after SFZYD treatment. In addition to inducing changes in the above metabolites, treatment with SFZYD also recovered the expression of genes related to hepatic mitochondrial dysfunction, including Ucp2, Cpt1α, and Ppargc1α, as well as the expression of genes involved in lipid metabolism and inflammation, without affecting glucose uptake or insulin signaling. Taken together, these findings suggest that treatment with SFZYD ameliorated obesity-induced systemic inflammation and hepatic steatosis by regulating inflammatory cytokine and adipokine levels in the circulation and various tissues. Moreover, treatment with SFZYD also reversed alterations in the levels of metabolites of the TCA cycle, the pentose phosphate pathway and aromatic amino acid metabolism. |
format | Online Article Text |
id | pubmed-5453538 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-54535382017-06-12 Shaofu Zhuyu decoction ameliorates obesity-mediated hepatic steatosis and systemic inflammation by regulating metabolic pathways Hong, Moonju Jung, Jeeyoun Park, Hee-Sook Lee, So Min Jeong, Nam-Joo Kim, Soon-Hee Lee, Kyoung-Won Lee, Ju-A Kim, Myung-Sunny PLoS One Research Article Shaofu Zhuyu decoction (SFZYD, also known as Sobokchugeo-tang), a classical prescription drug in traditional East Asian medicine, has been used to treat blood stasis syndrome (BSS). Hepatic steatosis is the result of excess caloric intake, and its pathogenesis involves internal retention of phlegm and dampness, blood stasis, and liver Qi stagnation. To evaluate the effects of treatment with SFZYD on obesity-induced inflammation and hepatic steatosis, we fed male C57BL/6N mice a high fat diet (HFD) for 8 weeks and then treated them with SFZYD by oral gavage for an additional 4 weeks. The results of histological and biochemical examinations indicated that SFZYD treatment ameliorates systemic inflammation and hepatic steatosis. A partial least squares-discriminant analysis (PLS-DA) scores plot of serum metabolites showed that HFD mice began to produce metabolites similar to those of normal chow (NC) mice after SFZYD administration. We noted significant alterations in the levels of twenty-seven metabolites, alterations indicating that SFZYD regulates the TCA cycle, the pentose phosphate pathway and aromatic amino acid metabolism. Increases in the levels of TCA cycle intermediate metabolites, such as 2-oxoglutaric acid, isocitric acid, and malic acid, in the serum of obese mice were significantly reversed after SFZYD treatment. In addition to inducing changes in the above metabolites, treatment with SFZYD also recovered the expression of genes related to hepatic mitochondrial dysfunction, including Ucp2, Cpt1α, and Ppargc1α, as well as the expression of genes involved in lipid metabolism and inflammation, without affecting glucose uptake or insulin signaling. Taken together, these findings suggest that treatment with SFZYD ameliorated obesity-induced systemic inflammation and hepatic steatosis by regulating inflammatory cytokine and adipokine levels in the circulation and various tissues. Moreover, treatment with SFZYD also reversed alterations in the levels of metabolites of the TCA cycle, the pentose phosphate pathway and aromatic amino acid metabolism. Public Library of Science 2017-06-01 /pmc/articles/PMC5453538/ /pubmed/28570676 http://dx.doi.org/10.1371/journal.pone.0178514 Text en © 2017 Hong et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Hong, Moonju Jung, Jeeyoun Park, Hee-Sook Lee, So Min Jeong, Nam-Joo Kim, Soon-Hee Lee, Kyoung-Won Lee, Ju-A Kim, Myung-Sunny Shaofu Zhuyu decoction ameliorates obesity-mediated hepatic steatosis and systemic inflammation by regulating metabolic pathways |
title | Shaofu Zhuyu decoction ameliorates obesity-mediated hepatic steatosis and systemic inflammation by regulating metabolic pathways |
title_full | Shaofu Zhuyu decoction ameliorates obesity-mediated hepatic steatosis and systemic inflammation by regulating metabolic pathways |
title_fullStr | Shaofu Zhuyu decoction ameliorates obesity-mediated hepatic steatosis and systemic inflammation by regulating metabolic pathways |
title_full_unstemmed | Shaofu Zhuyu decoction ameliorates obesity-mediated hepatic steatosis and systemic inflammation by regulating metabolic pathways |
title_short | Shaofu Zhuyu decoction ameliorates obesity-mediated hepatic steatosis and systemic inflammation by regulating metabolic pathways |
title_sort | shaofu zhuyu decoction ameliorates obesity-mediated hepatic steatosis and systemic inflammation by regulating metabolic pathways |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5453538/ https://www.ncbi.nlm.nih.gov/pubmed/28570676 http://dx.doi.org/10.1371/journal.pone.0178514 |
work_keys_str_mv | AT hongmoonju shaofuzhuyudecoctionamelioratesobesitymediatedhepaticsteatosisandsystemicinflammationbyregulatingmetabolicpathways AT jungjeeyoun shaofuzhuyudecoctionamelioratesobesitymediatedhepaticsteatosisandsystemicinflammationbyregulatingmetabolicpathways AT parkheesook shaofuzhuyudecoctionamelioratesobesitymediatedhepaticsteatosisandsystemicinflammationbyregulatingmetabolicpathways AT leesomin shaofuzhuyudecoctionamelioratesobesitymediatedhepaticsteatosisandsystemicinflammationbyregulatingmetabolicpathways AT jeongnamjoo shaofuzhuyudecoctionamelioratesobesitymediatedhepaticsteatosisandsystemicinflammationbyregulatingmetabolicpathways AT kimsoonhee shaofuzhuyudecoctionamelioratesobesitymediatedhepaticsteatosisandsystemicinflammationbyregulatingmetabolicpathways AT leekyoungwon shaofuzhuyudecoctionamelioratesobesitymediatedhepaticsteatosisandsystemicinflammationbyregulatingmetabolicpathways AT leejua shaofuzhuyudecoctionamelioratesobesitymediatedhepaticsteatosisandsystemicinflammationbyregulatingmetabolicpathways AT kimmyungsunny shaofuzhuyudecoctionamelioratesobesitymediatedhepaticsteatosisandsystemicinflammationbyregulatingmetabolicpathways |